slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 17,191-17,220
Pages 1,349
Rows per page 30
Beat
17,191-17,220 of 40,452
13
Includes footnotes regarding total gross loans and subsector definitions.Pathward Financial | Results Presentation Deck | 26 slides · Meta Financial Group
Conference presentation Investor relations Beat · DesireLoop · Cost Of Inaction1 hit
14
The slide provides a detailed breakdown of loan exposure, asset quality, and pandemic-related relief efforts.Pathward Financial | Results Presentation Deck | 26 slides · Meta Financial Group
Conference presentation Investor relations Beat · DesireLoop · Cost Of Inaction1 hit
10
The slide uses a categorization framework to map competitors against specific therapeutic modalities (Cell Therapies, Gene Therapies, Other).Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Market Size1 hit
11
The slide uses a Gantt-style chart to represent clinical trial progress for various oncology and gene therapy candidates.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
12
Poseida Therapeutics | IPO Presentation Deck | 34 slidesPoseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
13
The slide uses a process diagram to show cell differentiation and a callout box to list clinical benefits.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · ProductLoop · Cost Of Inaction1 hit
14
Poseida Therapeutics | IPO Presentation Deck | 34 slidesPoseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · ProductLoop · Cost Of Inaction1 hit
15
The slide highlights clinical trial results for an autologous product as a stepping stone to allogeneic development.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
16
Uses patient success stories as clinical evidence of product efficacy.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
17
Includes a process flow diagram and a specific technical callout for Cas-CLOVER gene editing.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
18
The slide uses a biological diagram to explain the mechanism of T-cell activation and a line chart to show the performance improvement.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
19
The slide uses two distinct chart types (bar and dot plot) to highlight two key performance metrics of the technology.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
20
The slide compares autologous (101) vs allogeneic (ALLO1) CAR-T therapy efficacy in tumor reduction.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
21
Slide 20 of a pitch deck, showing longitudinal efficacy data.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
22
Uses a before-after framing to contrast standard multi-dose therapy with the company's single-dose, self-renewing approach.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
23
Data presented at SITC 2017. Includes both imaging and caliper measurement data.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
24
The slide uses a quadrant key to identify T-cell subsets (Teff, TSCM, Tem, Tcm) and highlights the persistence of TSCM cells post-tumor elimination.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
25
The slide uses a combination of a table for market potential, a biological diagram for mechanism, and bar charts for efficacy and safety.Poseida Therapeutics | IPO Presentation Deck | 34 slides · Poseida Therapeutics
Pitch deck Investment bank Beat · Product1 hit
12
The table highlights the limitations of current pan-FGFR inhibitors (Pemigatinib, Infigratinib, TAS-120, Erdafitinib) regarding hyperphosphatemia and discontinuation rates.Relay Therapeutics | IPO Presentation Deck | 25 slides · Relay Therapeutics
Pitch deck Investment bank Beat · Competitive Analysis1 hit
23
The slide uses a split-layout to contrast operational progress with financial health.Relay Therapeutics | IPO Presentation Deck | 25 slides · Relay Therapeutics
Pitch deck Investment bank Beat · Financials1 hit
08
The chart displays a transition from actuals (2018-2019) to estimates (2020-2021).Rush Street | SPAC Presentation Deck | 37 slides · Rush Street Interactive
Pitch deck Investment bank Beat · Financials1 hit
09
The table highlights Rush Street Interactive in a light blue column, suggesting it is the focus company.Rush Street | SPAC Presentation Deck | 37 slides · Rush Street Interactive
Pitch deck Investment bank Beat · Financials1 hit
12
The slide uses a bar chart to compare market share and revenue, with additional context on total addressable market projections and RSI's YTD performance.Rush Street | SPAC Presentation Deck | 37 slides · Rush Street Interactive
Pitch deck Investment bank Beat · Competition1 hit
13
The slide uses a comparison table to establish market leadership and operational superiority.Rush Street | SPAC Presentation Deck | 37 slides · Rush Street Interactive
Pitch deck Investment bank Beat · Competition1 hit
14
This slide serves as a section divider or introduction to the market sizing section of the pitch deck.Rush Street | SPAC Presentation Deck | 37 slides · Rush Street Interactive
Pitch deck Investment bank Beat · Problem1 hit
15
Rush Street | SPAC Presentation Deck | 37 slidesRush Street | SPAC Presentation Deck | 37 slides · Rush Street Interactive
Pitch deck Investment bank Beat · Problem1 hit
08
The slide uses a three-column structure to categorize business strengths.Vasta Platform | IPO Presentation Deck | 29 slides · Vasta Educação
Pitch deck Investment bank Beat · Solution1 hit
09
Vasta Platform | IPO Presentation Deck | 29 slidesVasta Platform | IPO Presentation Deck | 29 slides · Vasta Educação
Pitch deck Investment bank Beat · Solution1 hit
10
Vasta Platform | IPO Presentation Deck | 29 slidesVasta Platform | IPO Presentation Deck | 29 slides · Vasta Educação
Pitch deck Investment bank Beat · Solution1 hit
11
The central diagram is a hub-and-spoke model representing the Plurall platform ecosystem.Vasta Platform | IPO Presentation Deck | 29 slides · Vasta Educação
Pitch deck Investment bank Beat · Solution1 hit